New Drug Therapy Initiative

As the lead funding partner in a new $78-million study of the effectiveness of Alzheimer's medications, the Province will provide PharmaCare coverage of three cholinesterase inhibitors for the first time. The Alzheimer's Drug Therapy Initiative will gather clinical evidence on who will benefit from these drugs and what the benefit will be for people in the mild to moderate stages of Alzheimer's disease. The initiative will last up to three years and involve more than 25,000 British Columbians.